


## Product datasheet

# Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal ab180176

Recombinant RabMAb

[1 References](#) [4 Images](#)

### Overview

|                            |  |
|----------------------------|--|
| <b>Product name</b>        | Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal  |
| <b>Description</b>         | Rabbit monoclonal [EPR12846] to Tropomyosin 2 - C-terminal   |
| <b>Host species</b>        | Rabbit   |
| <b>Tested applications</b> | <b>Suitable for:</b> IP, WB<br><b>Unsuitable for:</b> Flow Cyt, ICC/IF or IHC-P  |
| <b>Species reactivity</b>  | <b>Reacts with:</b> Human<br><b>Predicted to work with:</b> Mouse, Rat    |
| <b>Immunogen</b>           | Synthetic peptide within Human Tropomyosin 2 aa 200 to the C-terminus (internal sequence) (Cysteine residue). The exact sequence is proprietary.<br>Database link: <a href="#">P07951</a>  |
| <b>Positive control</b>    | WB: HeLa, HT-1080, fetal muscle and heart lysates, Human fetal muscle lysate. MYC and DDK-tagged Recombinant Human TPM2 protein (Full length)  |
| <b>General notes</b>       | This product is a recombinant monoclonal antibody, which offers several advantages including: <ul style="list-style-type: none"> <li>- High batch-to-batch consistency and reproducibility</li> <li>- Improved sensitivity and specificity</li> <li>- Long-term security of supply</li> <li>- Animal-free production</li> </ul> For more information <a href="#">see here</a> .<br>Our RabMAb <sup>®</sup> technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to <a href="#">RabMAb<sup>®</sup> patents</a> . |

### Properties

|                             |   |
|-----------------------------|---|
| <b>Form</b>                 | Liquid  |
| <b>Storage instructions</b> | Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.       |
| <b>Storage buffer</b>       | pH: 7.20<br>Preservative: 0.01% Sodium azide<br>Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture |

|                     |                    |
|---------------------|--------------------|
|                     | supernatant        |
| <b>Purity</b>       | Protein A purified |
| <b>Clonality</b>    | Monoclonal         |
| <b>Clone number</b> | EPR12846           |
| <b>Isotype</b>      | IgG                |

## Applications


**The Abpromise guarantee** Our **Abpromise guarantee** covers the use of ab180176 in the following tested applications. The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

| Application | Abreviews | Notes  |
|-------------|-----------|--|
| IP          |           | 1/10 - 1/100.  |
| WB          |           | 1/1000 - 1/5000. Predicted molecular weight: 33 kDa. |

**Application notes** Is unsuitable for Flow Cyt, ICC/IF or IHC-P.

## Target

|   |  |
|---|--|
| <b>Function</b>                         | Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction. Smooth muscle contraction is regulated by interaction with caldesmon. In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments. The non-muscle isoform may have a role in agonist-mediated receptor internalization.  |
| <b>Tissue specificity</b>               | Present in primary breast cancer tissue, absent from normal breast tissue.   |
| <b>Involvement in disease</b>           | Nemaline myopathy 4 (NEM4) [MIM:609285]: A form of nemaline myopathy. Nemaline myopathies are muscular disorders characterized by muscle weakness of varying severity and onset, and abnormal thread-or rod-like structures in muscle fibers on histologic examination. Nemaline myopathy type 4 presents from infancy to childhood with hypotonia and moderate-to-severe proximal weakness with minimal or no progression. Major motor milestones are delayed but independent ambulation is usually achieved, although a wheelchair may be needed in later life. Note=The disease is caused by mutations affecting the gene represented in this entry.<br>Arthrogryposis, distal, 1A (DA1A) [MIM:108120]: A form of distal arthrogryposis, a disease characterized by congenital joint contractures that mainly involve two or more distal parts of the limbs, in the absence of a primary neurological or muscle disease. Distal arthrogryposis type 1 is characterized largely by camptodactyly and clubfoot. Hypoplasia and/or absence of some interphalangeal creases is common. The shoulders and hips are less frequently affected. Note=The disease is caused by mutations affecting the gene represented in this entry. |
| <b>Sequence similarities</b>            | Belongs to the tropomyosin family.   |
| <b>Domain</b>                           | The molecule is in a coiled coil structure that is formed by 2 polypeptide chains. The sequence exhibits a prominent seven-residues periodicity.   |
| <b>Post-translational modifications</b> | Phosphorylated on Ser-61 by PIK3CG. Phosphorylation on Ser-61 is required for ADRB2 internalization.   |
| <b>Cellular localization</b>            | Cytoplasm > cytoskeleton.  |



Western blot - Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)

**All lanes :** Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176) at 1/1000 dilution

**Lane 1 :** MYC and DDK-tagged Recombinant Human TPM1 protein (Full length)

**Lane 2 :** MYC and DDK-tagged Recombinant Human TPM2 protein (Full length)

**Lane 3 :** MYC and DDK-tagged Recombinant Human TPM3 protein (Full length)

**Lane 4 :** GST-tagged Recombinant Human TPM4 protein (Full length)

**Secondary**


**All lanes :** Goat Anti-Rabbit IgG H&L (HRP) (**ab97051**) at 1/20000 dilution

**Predicted band size:** 33 kDa

**Observed band size:** 42 kDa


**Exposure time:** 180 seconds

Blocking buffer and concentration: 5% NFDM/TBST



Immunoprecipitation - Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)

Western blot analysis on immunoprecipitation pellet from Human fetal muscle lysate labeling Tropomyosin 2 using ab180176 at 1/10.



Western blot - Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)

**All lanes :** Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176) at 1/1000 dilution

**Lane 1 :** Fetal heart lysate

**Lane 2 :** HeLa cell lysate

**Lane 3 :** HT-1080 cell lysate

**Lane 4 :** Fetal muscle lysate

Lysates/proteins at 10 µg per lane.

#### Secondary

**All lanes :** Standard HRP labeled goat anti-rabbit at 1/2000 dilution

Developed using the ECL technique.

**Predicted band size:** 33 kDa

#### Why choose a recombinant antibody?



**Research with confidence**  
Consistent and reproducible results



**Long-term and scalable supply**  
Recombinant technology



**Success from the first experiment**  
Confirmed specificity



**Ethical standards compliant**  
Animal-free production

Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

#### Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish

- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

#### **Terms and conditions**

---

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors